What changed from existing technology?
This study compared two types of blood collection tubes for liquid biopsies, which are used to detect cancer DNA in blood. It found that one tube type (Streck) collected more DNA than the other (Sarstedt S-Monovette) when tested right away.
This is the first formal evaluation of the Sarstedt S-Monovette blood collection tube's performance in liquid biopsies compared to a reference standard.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
ll-free DNA stability and cell-free DNA purity. Thirty patients undergoing liquid biopsy for clinical follow-up were enrolled. DNA yield was estimated by plas
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The results suggest that Streck tubes may be more effective than Sarstedt S-Monovette tubes for collecting cell-free DNA in liquid biopsies, but further research is needed to confirm these findings.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.